WallStSmart

Abbott Laboratories (ABT)vsTalen Energy Corporation (TLN)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Abbott Laboratories generates 1241% more annual revenue ($45.13B vs $3.37B). ABT leads profitability with a 13.9% profit margin vs -0.6%. ABT earns a higher WallStSmart Score of 56/100 (C).

ABT

Buy

56

out of 100

Grade: C

Growth: 4.0Profit: 6.0Value: 6.0Quality: 4.8
Piotroski: 3/9

TLN

Hold

48

out of 100

Grade: D+

Growth: 8.0Profit: 4.0Value: 4.0Quality: 5.3
Piotroski: 4/9Altman Z: 0.70
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ABTUndervalued (+3.7%)

Margin of Safety

+3.7%

Fair Value

$87.55

Current Price

$84.32

$3.23 discount

UndervaluedFair: $87.55Overvalued
TLNSignificantly Overvalued (-76.5%)

Margin of Safety

-76.5%

Fair Value

$200.88

Current Price

$386.37

$185.49 premium

UndervaluedFair: $200.88Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ABT2 strengths · Avg: 8.5/10
Market CapQuality
$151.56B9/10

Large-cap with strong market position

Price/BookValuation
2.8x8/10

Reasonable price relative to book value

TLN2 strengths · Avg: 9.0/10
Revenue GrowthGrowth
78.9%10/10

Revenue surging 78.9% year-over-year

EPS GrowthGrowth
34.5%8/10

Earnings expanding 34.5% YoY

Areas to Watch

ABT2 concerns · Avg: 2.5/10
Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

EPS GrowthGrowth
-19.7%2/10

Earnings declined 19.7%

TLN4 concerns · Avg: 2.3/10
Price/BookValuation
16.2x4/10

Trading at 16.2x book value

Return on EquityProfitability
-1.9%2/10

ROE of -1.9% — below average capital efficiency

Altman Z-ScoreHealth
0.702/10

Distress zone — elevated risk

Profit MarginProfitability
-0.6%1/10

Currently unprofitable

Comparative Analysis Report

WallStSmart Research

Bull Case : ABT

The strongest argument for ABT centers on Market Cap, Price/Book. PEG of 1.29 suggests the stock is reasonably priced for its growth.

Bull Case : TLN

The strongest argument for TLN centers on Revenue Growth, EPS Growth. Revenue growth of 78.9% demonstrates continued momentum.

Bear Case : ABT

The primary concerns for ABT are Piotroski F-Score, EPS Growth.

Bear Case : TLN

The primary concerns for TLN are Price/Book, Return on Equity, Altman Z-Score.

Key Dynamics to Monitor

ABT profiles as a value stock while TLN is a hypergrowth play — different risk/reward profiles.

TLN carries more volatility with a beta of 1.67 — expect wider price swings.

TLN is growing revenue faster at 78.9% — sustainability is the question.

ABT generates stronger free cash flow (916M), providing more financial flexibility.

Bottom Line

ABT scores higher overall (56/100 vs 48/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Abbott Laboratories

HEALTHCARE · MEDICAL DEVICES · USA

Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.

Visit Website →

Talen Energy Corporation

UTILITIES · UTILITIES - INDEPENDENT POWER PRODUCERS · USA

Talen Energy Corporation (Ticker: TLN) is a leading power generation and infrastructure company based in the United States, specializing in the development and operation of reliable and sustainable energy solutions. With a diverse portfolio that includes both traditional and renewable energy sources, Talen Energy is committed to supporting the evolving energy landscape while prioritizing environmental stewardship. The company is strategically positioned to meet growing electricity demand, leverage technological advancements, and enhance grid resilience, making it an attractive investment opportunity for institutional investors focused on the energy sector's transformation.

Want to dig deeper into these stocks?